RT Journal Article
SR Electronic
T1 SARS-CoV-2 infection in pregnancy is associated with robust inflammatory response at the maternal-fetal interface
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.25.21250452
DO 10.1101/2021.01.25.21250452
A1 Lu-Culligan, Alice
A1 Chavan, Arun R.
A1 Vijayakumar, Pavithra
A1 Irshaid, Lina
A1 Courchaine, Edward M.
A1 Milano, Kristin M.
A1 Tang, Zhonghua
A1 Pope, Scott D.
A1 Song, Eric
A1 Vogels, Chantal B.F.
A1 Lu-Culligan, William J.
A1 Campbell, Katherine H.
A1 Casanovas-Massana, Arnau
A1 Bermejo, Santos
A1 Toothaker, Jessica M.
A1 Lee, Hannah J.
A1 Liu, Feimei
A1 Schulz, Wade
A1 Fournier, John
A1 Muenker, M. Catherine
A1 Moore, Adam J.
A1 ,
A1 Konnikova, Liza
A1 Neugebauer, Karla M.
A1 Ring, Aaron
A1 Grubaugh, Nathan D.
A1 Ko, Albert I.
A1 Morotti, Raffaella
A1 Guller, Seth
A1 Kliman, Harvey J.
A1 Iwasaki, Akiko
A1 Farhadian, Shelli F.
YR 2021
UL http://medrxiv.org/content/early/2021/01/26/2021.01.25.21250452.abstract
AB Pregnant women appear to be at increased risk for severe outcomes associated with COVID-19, but the pathophysiology underlying this increased morbidity and its potential impact on the developing fetus is not well understood. In this study of pregnant women with and without COVID-19, we assessed viral and immune dynamics at the placenta during maternal SARS-CoV-2 infection. Amongst uninfected women, ACE2 was detected by immunohistochemistry in syncytiotrophoblast cells of the normal placenta during early pregnancy but was rarely seen in healthy placentas at full term. Term placentas from women infected with SARS-CoV-2, however, displayed a significant increase in ACE2 levels. Using immortalized cell lines and primary isolated placental cells, we determined the vulnerability of various placental cell types to direct infection by SARS-CoV-2 in vitro. Yet, despite the susceptibility of placental cells to SARS-CoV-2 infection, viral RNA was detected in the placentas of only a subset (∼13%) of women in this cohort. Through single cell transcriptomic analyses, we found that the maternal-fetal interface of SARS-CoV-2-infected women exhibited markers associated with pregnancy complications, such as preeclampsia, and robust immune responses, including increased activation of placental NK and T cells and increased expression of interferon-related genes. Overall, this study suggests that SARS-CoV-2 is associated with immune activation at the maternal-fetal interface even in the absence of detectable local viral invasion. While this likely represents a protective mechanism shielding the placenta from infection, inflammatory changes in the placenta may also contribute to poor pregnancy outcomes and thus warrant further investigation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementALC is supported by the National Institutes of Health (NIH) under Medical Scientist Training Program (MSTP) grant T32GM007205 and National Institute of Child Health & Development (NICHD) grant F30HD093350. ARC is supported by Irvington Postdoctoral Fellowship from Cancer Research Institute. AI is an investigator of the Howard Hughes Medical Institute. This work was supported by NIH K23MH118999 (SFF), R01AI157488 (SFF and AI), U01DA040588- 05S (KMN), the Beatrice Kleinberg Neuwirth Fund (AK), and Fast Grant funding support from the Emergent Ventures at the Mercatus Center (AI). No NIH funding was used in the acquisition of placental tissue derived from healthy terminations.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Informed consent was given and signed by all patients. All samples collected were approved by the respective Institutional Review Boards at Yale (protocol 1208010742), Bnai Zion Medical Center (protocol 021-06-972), and the University of Pittsburgh (PRO18010491).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw sequence data will be deposited to the Gene Expression Omnibus (GEO) repository at the National Center for Biotechnology Information (NCBI).